About Us
Who We Are
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. We are a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. Approximately 21,000 oncology professionals are involved in Group research. They include physicians, translational scientists, and associated research professionals from the member institutions, along with advocates.
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, ECOG-ACRIN is a vibrant component of the National Institutes of Health's National Cancer Institute (NCI) through its National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP). The NCI is our primary funder, through grants from these and other programs to our nonprofit ECOG-ACRIN Medical Research Foundation. We also receive financial support from private sector organizations through philanthropy and collaborations.
Our Mission
Our mission is to reduce the burden of cancer and improve the quality of life and survival of adult patients with cancer.
What We Do
Our research capacity is unique. We design and conduct clinical trials that cross the spectrum of cancer types that occur in adults. Our cancer treatment trials boldly integrate the latest imaging and pathology-based biomarker discoveries. Meanwhile, imaging-specific trials evaluate new strategies for cancer prevention, screening, or treatment in specific cancer types. Five overarching scientific themes drive all of the Group's research: precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms and matched novel therapies; and advancing standards of care in broad populations of cancer patients and those at risk. We conduct cancer research through three scientific programs: Therapeutic Studies, Biomarker Sciences, and Cancer Control and Outcomes. These distinct--yet complementary--programs provide a matrix-style organization for specific groups of investigators and advocates to contribute to trial development and implementation.
